STING1 and neoplasm: Vectors carrying the STING activator, such as lipid nanoparticles (LNPs) and irradiated tumour cell‐derived microparticles (RMPs), deliver STING agonists to specific sites of urologic malignancies to enhance cytokine release, thus maximising therapeutic efficacy and minimising systemic toxicity.